Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model

American Journal of Physiology - Renal Physiology

Volumn 294, Issue 5, 2008, Pages

  Nishimura, Hayato ^a   Ito, Yasuhiko ^a,c   Mizuno, Masashi ^a   Tanaka, Akio ^b   Morita, Yoshiki ^a   Maruyama, Shoichi ^a   Yuzawa, Yukio ^a   Matsuo, Seiichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUBU ROSAI HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

Neoangiogenesis; Renin angiotensin aldosterone system; Serum and glucocorticoid induced kinase 1; Ultrafiltration failure

Indexed keywords

ALDOSTERONE; ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; COLLAGEN TYPE 3; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; TEMOCAPRIL; TRANSFORMING GROWTH FACTOR BETA; HORMONE ANTAGONIST; IMMEDIATE EARLY PROTEIN; PROTEIN SERINE THREONINE KINASE; RNA; SERUM GLUCOCORTICOID REGULATED KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE;

ALDOSTERONE BLOOD LEVEL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MODEL; FIBROBLAST; FIBROSIS; GENE EXPRESSION; INFLAMMATORY CELL; MACROPHAGE MIGRATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM; PERITONEUM FIBROSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; CELL CULTURE; DRUG ANTAGONISM; ELECTRON MICROSCOPY; GENETICS; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MACROPHAGE; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBROBLASTS; FIBROSIS; HORMONE ANTAGONISTS; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICROSCOPY, ELECTRON; NEUTROPHILS; PERITONITIS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SPIRONOLACTONE;

EID: 45149134451     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00565.2007     Document Type: Article

References (60)

1. Aldigier JC, Kanjanbuch T, Ma L, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314, 2005.
2. Bellingan GJ, Caldwell H, Howie SE, Dransfield I, Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol 157: 2577-2585, 1996.
3. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor-β in human disease. N Engl J Med 342: 1350-1358, 2000.
4. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
5. Combet S, Van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, Balligand JL, Lameire N, Devuyst O. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 10: 2185-2196, 1999.
6. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 66: 2437-2445, 2004.
7. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11: 498-506, 1996.
8. Del Peso G, Fernández-Reyes MJ, Hevia C, Bajo MA, Castro MJ, Cirugeda A, Sánchez-Tomero JA, Selgas R. Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant 20: 1201-1206, 2005.
9. Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, Sun GP, Kohno M, Fujita M, Abe Y, Nishiyama A. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res 29: 169-178, 2006.
10. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288: F433-F442, 2005.
11. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Sano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66: 1493-1502, 2004.
12. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 26: 313-321, 2005.
13. Guo H, Leung JCK, Lam MF, Chan LYY, Tsang AWL, Lan HY, Lai KN. Smad7 transgene attenuates peritoneal fibrosis in uremic rats treated with peritoneal dialysis. J Am Soc Nephrol 18: 2689-2703, 2007.
14. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006.
15. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
16. Henderson IS, Dobbie JW, Zaki MA, Wilson LS. Structure of peritoneum and changes brought about by infection. Contr Nephrol 57: 30-40, 1987.
17. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003.
18. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714, 2001.
19. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 65: 1927-1936, 2004.
20. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53: 853-861, 1998.
21. Ito Y, Goldschmeding R, Bende R, Claessen N, Chand M, Kleij L, Rabelink T, Weening JJ, Aten J. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 12: 472-484, 2001.
22. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter T. Effect of aldosterone on renal transforming growth factor-β. Am J Physiol Renal Physiol 286: F1059-F1062, 2004.
23. 1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation. Hypertens Res 27: 509-515, 2004.
24. Kawaguchi Y, Ishizaki T, Imada A, Ohhira S, Nakamoto H, Hiramatsu M, Maeda K, Ota K. Searching for the reasons for drop-out from peritoneal dialysis: a nationwide survey in Japan. Perit Dial Int 23: S175-S177, 2003.
25. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109: 2213-2220, 2004.
26. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, Kim JJ, Moberly JB. Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int 19: S384-S387, 1999.
27. Lai KN, Lai KB, Lam CWK, Chan TM, Li FK, Leung JCK. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 35: 644-652, 2000.
28. Lang F, Klingel K, Wagner CA, Stegen C, Wärntges S, Friedrich B, Lanzendörfer M, Melzig J, Moschen I, Steuer S, Waldegger S, Sauter M, Paulmichl M, Gerke V, Risler T, Gamba G, Capasso G, Kandolf R, Hebert SC, Massry SG, Bröer S. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci USA 97: 8157-8162, 2000.
29. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69: 1064-1072, 2006.
30. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 23: 530-541, 2003.
31. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, Kelly MM. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 16: 425-436, 2005.
32. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TS, Gauldie J. Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 12: 2029-2039, 2001.
33. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 21: S368-S372, 2001.
34. Mateijsen MA, Van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, Krediet RT. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 19: 517-525, 1999.
35. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Int 25: S48-S56, 2005.
36. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, Nishiyama A. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46: 1039-1045, 2005.
37. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17: 3438-3446, 2006.
38. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, Suzuki H. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 21: S349-S353, 2001.
39. Nakayama M. Fluid status and its management in Japanese peritoneal dialysis patients. Perit Dial Int 26: 144-149, 2006.
40. Ni J, Moulin P, Gianello P, Feron O, Balligand JL, Devuyst O. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 14: 3205-3216, 2003.
41. Ota K, Mineshima M, Watanabe N, Naganuma S. Functional deterioration of the peritoneum: does it occur in the absence of peritonitis? Nephrol Dial Transplant 2: 30-33, 1987.
42. Paolo ND, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 20: S5-S96, 2000.
43. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
44. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717, 1999.
45. Ponda MP, Hostetter TH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 1: 668-677, 2006.
46. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112: 1435-1443, 2005.
47. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998.
48. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999.
49. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 18: 97-102, 1991.
50. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, del Peso G, de Alvaro F. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 23: 64-73, 1994.
51. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49: 355-364, 2007.
52. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43: 1056-1064, 2004.
53. Topley N, Liberek T, Davenport A, Li FK, Fear H, Williams JD. Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int 56: S17-S21, 1996.
54. Vallon V, Huang DY, Grahammer F, Wyatt AW, Osswald H, Wulff P, Kuhl D, Lang F. SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess. Am J Physiol Regul Integr Comp Physiol 289: R395-R401, 2005.
55. Vallon V, Wyatt AW, Klingel K, Huang DY, Hussain A, Berchtold S, Friedrich B, Grahammer F, BelAiba RS, Görlach A, Wulff P, Daut J, Dalton ND, Ross J Jr, Flögel U, Schrader J, Osswald H, Kandolf R, Kuhl D, Lang F. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med 84: 396-404, 2006.
56. Vriese ASD, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 14: 2109-2118, 2003.
57. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13: 470-479, 2002.
58. Wiliams JD, Topley N, Craig KJ, Marckenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66: 408-418, 2004.
59. Xie J, Wu K, Wang W, Li Y, Ren H, Chen N. Role of angiotensin II in peritoneal fibrosis and its related signal pathways (Abstract). J Am Soc Nephrol 17: 756A, 2006.
60. Zareie M, Fabbrini P, Hekking LHP, Keuning ED, ter Wee PM, Beelen RHT, van den Born J. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. J Am Soc Nephrol 17: 3447-3457, 2006.